We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+38.03%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$439M
AUM Growth
+$18.8M
Cap. Flow
-$56.2M
Cap. Flow %
-12.79%
Top 10 Hldgs %
79.78%
Holding
33
New
6
Increased
4
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$10.5M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.01M
3
CBAY
Cymabay Therapeutics
CBAY
+$3.98M
4
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$3.63M
5
KURA icon
Kura Oncology
KURA
+$2.92M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$24.1M
2
INCY icon
Incyte
INCY
+$12.6M
3
MDCO
Medicines Co
MDCO
+$11.6M
4
PTCT icon
PTC Therapeutics
PTCT
+$8.81M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$6.47M

Sector Composition

Rank Sector Weight
1 Healthcare 91.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIGR
26
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.52M 0.35%
4,611
– –
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.69B
$1.17M 0.27%
100,000
-134,220
-57% -$1.65M
NBRV
28
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$710K 0.16%
347
-360
-51% -$844K
ONTXW
29
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$528K 0.12%
308,793
+67,149
+28% +$36.1K
TRAW icon
30
Traws Pharma
TRAW
$6.85M
$92K 0.02%
43
-11
-20% -$114K
INCY icon
31
Incyte
INCY
$24.2B
– –
-100,000
Closed -$12.6M
SGEN
32
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-125,000
Closed -$6.47M
MDCO
33
CALL
DELISTED
Medicines Co
MDCO
– –
-530,600
Closed -$20.2M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Boxer Capital held 33 positions worth $439M, up 4.5% from $421M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Boxer Capital withdrew a net $56.2M in Q3 2017, closing 3 positions and reducing 9 holdings. Its most notable exit was Incyte, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 83% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Sio Gene Therapies Inc. Common Stock worth $3.44M.

  • Boxer Capital's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 62,500 shares worth $3.44M.
  • Boxer Capital added most to Cymabay Therapeutics in Q3 2017, an estimated $3.98M increase.
  • Boxer Capital's biggest Q3 2017 reduction was Esperion Therapeutics, cutting an estimated $24.1M.
  • Boxer Capital fully exited Incyte in Q3 2017, selling an estimated $12.6M.
  • Boxer Capital's ten largest holdings make up 80% of its $439M portfolio in Q3 2017.
  • Boxer Capital opened 6 new positions and closed 3 in Q3 2017.
  • Boxer Capital's portfolio value rose 4.5% quarter-over-quarter to $439M.

Based on Boxer Capital's 13F filing for Q3 2017, filed 14 Nov 2017.